Skip to main content
Equibles
MGX logo

MGX · Metagenomi Therapeutics, Inc. · Metrics

Track MGX — free

Use MGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.86 +0.03 (+3.43%)
Rebalance outlook locked
Market Cap
$31.40M
Shares
37.78M
Volume · Oct 21 18.09K Avg daily vol (3M) 156.43K

MGX metrics

77 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.83
Market cap
$31.40M

Price action

20 metrics
Price change (1W)
-9.4%
Price change (30D)
-25.8%
Price change (3M)
-31.9%
Price change (6M)
-44.6%
Price change (YTD)
-48.7%
Price change (1Y)
-75.2%
Trailing year
Price change (5Y)
—
52-week high
$3.35
52-week low
$0.78
Change from 52-week high
-75.2%
Change from 52-week low
+6.0%
Annualized volatility
56.2%
Annualized volatility (3M)
41.4%
Beta
1.5
RSI (14D)
28.3
Price vs SMA 50
-25.1%
Price vs SMA 200
-37.6%
Avg volume (3M)
156,433
Relative volume
0.6
Average dollar volume
$175,518

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
37.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.4×
reciprocal yield 72.8%
P / book
0.3
reciprocal yield 367.1%
FCF yield
-279.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-304.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.8×
reciprocal yield 119.8%
EV / revenue historical average (5Y)
0.8×
reciprocal yield 119.8%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-12

Profitability

9 metrics
Gross margin
—
Operating margin
-380.9%
Trailing 12 months
Net margin
-348.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$100.57M
Net income (TTM)
−$93.46M
Trailing 12 months
Diluted EPS (TTM)
$-2.48
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.60
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.68
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-2.49
Operating cash flow per diluted share (TTM)
$-2.28
Free cash flow per diluted share (TTM)
$-2.29
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$2.36
Stock compensation per diluted share (TTM)
$0.28
Book value per share
$4.22

Growth

11 metrics
Revenue growth YoY
-69.8%
Year over year
Net income growth YoY
—
Revenue (TTM)
$22.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-83.0%
Return on assets
-53.8%
Debt / equity
0.0
Current ratio
4.5
EBITDA (TTM)
—
Free cash flow (TTM)
−$85.80M
Quick ratio
4.5
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$39.03M
Latest balance sheet
Cash & equivalents
$39.03M
Total assets
$173.70M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$85.49M
Capital expenditures (TTM)
$309,000
R&D (TTM)
$88.60M
SG&A (TTM)
—
Stock compensation (TTM)
$10.52M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
43
13F filer change QoQ
-5
Institutional ownership
16.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
8.0%
Private-fund adviser ownership
7.7%
Active holders' share change QoQ
-3.4%
Holder tenure
6.7
Price vs estimated holder cost
-51.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.9%

Short interest

3 metrics
Short interest
3.4%
Latest settlement · 10.5 days to cover
Days to cover
10.5d
Short-squeeze score
54 / 100

Insider activity

2 metrics
Net insider buying (90D)
$18,294
Insider-sentiment score
61 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1785279 CUSIP 59102M104 13F (30d) 2 filings 2 filers Visit website Investor relations